Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis.

Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
The Journal of Immunology (Impact Factor: 5.36). 06/2005; 174(10):6440-8. DOI: 10.4049/jimmunol.174.10.6440
Source: PubMed

ABSTRACT We have demonstrated previously that local, adenoviral-mediated gene transfer of viral IL-10 to a single joint of rabbits and mice with experimental arthritis can suppress disease in both the treated and untreated contralateral joints. This contralateral effect is mediated in part by APCs able to traffic from the treated joint to lymph nodes as well as to untreated joints. Moreover, injection of dendritic cells (DC) genetically modified to express IL-4 or Fas ligand was able to reverse established murine arthritis. To examine the ability of exosomes derived from immunosuppressive DCs to reduce inflammation and autoimmunity, murine models of delayed-type hypersensitivity and collagen-induced arthritis were used. In this study, we demonstrate that periarticular administration of exosomes purified from either bone marrow-derived DCs transduced ex vivo with an adenovirus expressing viral IL-10 or bone marrow-derived DCs treated with recombinant murine IL-10 were able to suppress delayed-type hypersensitivity responses within injected and untreated contralateral joints. In addition, the systemic injection of IL-10-treated DC-derived exosomes was able suppress the onset of murine collagen-induced arthritis as well as reduce severity of established arthritis. Taken together, these data suggest that immature DCs are able to secrete exosomes that are involved in the suppression of inflammatory and autoimmune responses. Thus DC-derived exosomes may represent a novel, cell-free therapy for the treatment of autoimmune diseases.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Extracellular vesicle or EV is a term that encompasses all classes of secreted lipid membrane vesicles. Despite being scientific novelties, EVs are gaining importance as a mediator of important physiological and pathological intercellular activities possibly through the transfer of their cargo of protein and RNA between cells. In particular, exosomes, the currently best characterized EVs have been notable for their in vitro and in vivo immunomodulatory activities. Exosomes are nanometer-sized endosome-derived vesicles secreted by many cell types and their immunomodulatory potential is independent of their cell source. Besides immune cells such as dendritic cells, macrophages, and T cells, cancer and stem cells also secrete immunologically active exosomes that could influence both physiological and pathological processes. The immunological activities of exosomes affect both innate and adaptive immunity and include antigen presentation, T cell activation, T cell polarization to regulatory T cells, immune suppression, and anti-inflammation. As such, exosomes carry much immunotherapeutic potential as a therapeutic agent and a therapeutic target.
    Frontiers in Immunology 10/2014; 5:518.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell-based therapy, e.g., multipotent mesenchymal stromal cell (MSC) treatment, shows promise for the treatment of various diseases. The strong paracrine capacity of these cells and not their differentiation capacity, is the principal mechanism of therapeutic action. MSCs robustly release exosomes, membrane vesicles (~30-100 nm) originally derived in endosomes as intraluminal vesicles, which contain various molecular constituents including proteins and RNAs from maternal cells. Contained among these constituents, are small non-coding RNA molecules, microRNAs (miRNAs), which play a key role in mediating biological function due to their prominent role in gene regulation. The release as well as the content of the MSC generated exosomes are modified by environmental conditions. Via exosomes, MSCs transfer their therapeutic factors, especially miRNAs, to recipient cells, and therein alter gene expression and thereby promote therapeutic response. The present review focuses on the paracrine mechanism of MSC exosomes, and the regulation and transfer of exosome content, especially the packaging and transfer of miRNAs which enhance tissue repair and functional recovery. Perspectives on the developing role of MSC mediated transfer of exosomes as a therapeutic approach will also be discussed.
    Frontiers in Cellular Neuroscience 11/2014; 8:377. · 4.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Exosomes are extracellular vesicles released by many cells of the body. These small vesi-cles play an important part in intercellular communication both in the local environment and systemically, facilitating in the transfer of proteins, cytokines as well as miRNA between cells. The observation that exosomes isolated from immune cells such as dendritic cells (DCs) modulate the immune response has paved the way for these structures to be con-sidered as potential immunotherapeutic reagents. Indeed, clinical trials using DC derived exosomes to facilitate immune responses to specific cancer antigens are now underway. Exosomes can also have a negative effect on the immune response and exosomes iso-lated from regulatory T cells (Tregs) and other subsets of T cells have been shown to have immune suppressive capacities. Here, we review what is currently known about Treg derived exosomes and their contribution to immune regulation, as well as highlighting their possible therapeutic potential for preventing graft rejection, and use as diagnostic tools to assess transplant outcome. TREG EXOSOMES – IMMUNE MODULATORS Exosomes are small, cup-shaped, secreted membrane vesicles (approximately 50–100 nM in diameter) that are formed by the inward budding of endosomal membranes (1–6). Exosomes are released into the extracellular environment following the fusion of multivesicular endosomes with the plasma membrane (7). Sev-eral proteins involved in their biogenesis and release have been described and have recently been reviewed by Colombo et al. (7). Exosomes released by many immune and non-immune cells have been shown to have a range of physiological properties within the immune system. These include antigen presentation, immune regulation, and programed cell death, each of which is linked to the cell from which they are released (6, 7). They play an impor-tant role in intercellular communication and can act as shuttles for transferring proteins, miRNA, mRNA, and cytokines from one cell to another (8). Many cells of the body produce these extracellular vesicles (EVs) including those of the immune system such as CD4 + and CD8 + T cells, B cells, and dendritic cells (DCs). Exosomes from these cells have been shown to mediate either immune stimu-lation (DCs) or immune modulation (T cells) (9–14). Recently, the release of exosomes by murine CD4 + CD25 + Foxp3 + reg-ulatory T cells (Tregs), following TCR activation, was shown, initially by Smyth et al. (15) and later by Okoye et al. (16). In addition to CD4 + CD25 + Foxp3 + cells, other murine T cells with regulatory capacities were found to also release exosomes fol-lowing activation. Bryniarski et al. observed that "exosome like" particles were present in the supernatants of cultured CD8 + T cells with suppressive capacity (17), whilst Xie et al. observed that CD8 + CD25 + Foxp3 + T cells secreted exosomes capable of inhibiting DC induced CD8 + CTL responses (18). Exosome production by murine CD4 + CD25 + Foxp3 + Tregs appears to be quantitatively greater than other murine T cells, including naïve CD4 + and CD8 + T cells, T helper 1 (Th1), and Th17 cells, and is regulated by changes in intracellular cal-cium, hypoxia, and sphingolipids ceramide synthesis, as well as in the presence of IL-2 (16). Exosomes contribute significantly to the function of murine CD4 + CD25 + FoxP3 + Tregs, inhibiting the release of exosomes reversed these cells suppressive capabil-ities (16). In parallel, murine Tregs exosomes were found to be immune modulatory. Reduced CD4 + T cell proliferation and cytokine (IL-2 and IFNγ) release was observed in their pres-ence in vitro (15). The suppressive nature of Treg exosomes, in one study, has been attributed to the ectoenzyme CD73 (15). The loss of CD73 on Treg exosomes reversed their suppres-sive nature. Expression of both CD39 and CD73 on Tregs con-tributes to immune suppression through the production of the anti-inflammatory mediator adenosine (19–21). Binding of this molecule to adenosine receptors A2aR, expressed by activated T effector cells (Teffs) triggers intracellular cAMP leading to the inhi-bition of cytokine production, thereby limiting T cell responses (22). Given that adenosine was produced following incubation of CD73 expressing Treg exosomes with exogenous 5 AMP it is feasible that the release of exosomes expressing CD73 within the local environment increases the surface area by which this membrane-associated enzyme, and ultimately Treg suppression, can function (15). Several molecules associated with immune modulation includ-ing CD25 and CTLA-4, were also found on CD4 + CD25 + Foxp3 + Treg exosomes (15). Nolte-'t Hoen et al. have previously shown that exosomes, derived from anergic rat T cells, inhibited Teffs responses following co-culture with B cells and DCs in vitro (23).
    Frontiers in Immunology 12/2014; 5.

Full-text (2 Sources)

Available from
Jun 2, 2014